Accession Number : AD1016657


Title :   Use of a Novel Embryonic Mammary Stem Cell Gene Signature to Improve Human Breast Cancer Diagnostics and Therapeutic Decision Making


Descriptive Note : Technical Report,30 Sep 2012,29 Sep 2015


Corporate Author : University of North Carolina at Chapel Hill Chapel Hill United States


Personal Author(s) : Perou,Charles M ; Wahl,Geoffrey M ; Spike,Benjamin ; Lasken,Roger


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1016657.pdf


Report Date : 01 Dec 2015


Pagination or Media Count : 12


Abstract : Our major goals are to determine whether Fetal Mammary Stem Cell (fMaSC) signatures correlate with response to chemotherapy and metastasis in different breast cancer intrinsic subtypes (AIM1), and to develop single cell sequencing to produce highly refined fMaSC signatures (AIM2). Accomplishing these aims will enable us to: 1) better categorize distinct cell types within the fMaSC population, 2) identify biomarkers for prospective stem cell purification and in situ localization, and 3) identify candidate stem cell regulatory pathways that should reveal therapeutic targets and improved prognosticators and response biomarkers. In the most recent funding period, our bioinformatic analysis identified subsets of fMaSC signature genes that are coordinately expressed in archived human breast cancer gene expression data sets and assessed their prognostic and/or predictive power. We have thus far identified one subset exhibiting significant prognostic value distinct from existing and commonly used clinical variables in the preliminary data sets we have analyzed. We have also adapted a new microfluidics-based, single-cell capture and library preparation system to improve reproducibility in the generation of gene expression profiles from individual fMaSC. These advances provide proof of the principles underlying this grant and leave us well positioned to achieve its aims.


Descriptors :   breast cancer , cancer research , stems cells , Transcription(Genetics) , gene expression , Bioinformatics , biological markers , therapeutics


Distribution Statement : APPROVED FOR PUBLIC RELEASE